A phase IIb open label, randomized clinical trial evaluating efficacy and safety of Myrcludex B in combination with tenofovir in patients with chronic hepatitis B and D co-infections

Trial Profile

A phase IIb open label, randomized clinical trial evaluating efficacy and safety of Myrcludex B in combination with tenofovir in patients with chronic hepatitis B and D co-infections

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Myrcludex-B (Primary) ; Tenofovir
  • Indications Hepatitis B; Hepatitis D
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Apr 2017 According to a Hepatera media release, the interim results from the study will be available by the end of 2017.
    • 04 Apr 2017 Status changed from recruiting to active, no longer recruiting, according to a Hepatera media release.
    • 31 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top